{
  "ticker": "LLY",
  "target_date": "2025-07-30",
  "actual_date": "2025-07-30",
  "collected_at": "2025-12-08T12:04:49.691193",
  "price": {
    "open": 771.17,
    "high": 775.26,
    "low": 755.64,
    "close": 757.3020629882812,
    "volume": 4338700,
    "change_1d_pct": -0.38,
    "change_7d_pct": -0.28,
    "change_30d_pct": -5.88
  },
  "technicals": {
    "rsi_14": 42.56,
    "sma_20": 780.23,
    "sma_50": 770.31,
    "macd": 1.002,
    "macd_signal": 2.75,
    "macd_histogram": -1.748,
    "bb_upper": 812.64,
    "bb_lower": 747.83,
    "price_vs_sma20_pct": -2.94,
    "price_vs_sma50_pct": -1.69,
    "volume_ratio": 1.37
  },
  "fundamentals": {
    "market_cap": 892077539328,
    "pe_ratio": 48.75625,
    "forward_pe": 43.915047,
    "price_to_book": 37.46668,
    "price_to_sales": 15.013136,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.51,
    "pct_from_52w_low": 59.53
  },
  "macro": {
    "spy": {
      "price": 632.71,
      "change_1d_pct": -0.13,
      "change_7d_pct": 0.89
    },
    "vix": {
      "level": 15.48,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.38
    },
    "dollar_index": {
      "level": 99.94
    },
    "gold": {
      "price": 3295.8
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Farxiga and Jardiance pose affordability issues, says Maryland drug board",
      "source": "Yahoo",
      "datetime": 1753918007,
      "summary": "The state\u2019s independent body approved resolutions stating that both drugs present affordability challenges.",
      "url": "https://finnhub.io/api/news?id=e801b4d6b50d02879f37a253a213eaa7ef7c5f0b5ff3ddb27b5378cbed8b8753"
    },
    {
      "headline": "Novo Nordisk A/S (NVO) Could Lose To Eli Lilly, Warns Jim Cramer",
      "source": "Yahoo",
      "datetime": 1753902232,
      "summary": "We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO) came up during the show in the context of trade discussions between the US and Europe and potential tariffs on the pharmaceutical ",
      "url": "https://finnhub.io/api/news?id=5eb3ebff89e810996d62aa54d37ba10a652d9552a87c6c470d6f49953039f76d"
    },
    {
      "headline": "CVS Health Corporation (CVS) Is A Key Part Of Weight Loss Drug Distribution, Says Jim Cramer",
      "source": "Yahoo",
      "datetime": 1753902207,
      "summary": "We recently published 10 Stocks That Jim Cramer Talked About. CVS Health Corporation (NYSE:CVS) is one of the stocks Jim Cramer recently discussed. CVS Health Corporation (NYSE:CVS) is one of the largest pharmaceutical retailers in America. The shares have gained 36% year-to-date as the firm has enj",
      "url": "https://finnhub.io/api/news?id=aef2f83a67b0501ebfcadc4963b37f8e5623cf74c11cedfaaf6c33a899903752"
    },
    {
      "headline": "Eli Lilly and Company (LLY): Jim Cramer\u2019s \u201cBullish\u201d On News Of Tariffs",
      "source": "Yahoo",
      "datetime": 1753902163,
      "summary": "We recently published 10 Stocks That Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is one of Cramer\u2019s top pharmaceutical stocks. While the firm\u2019s weight loss drugs are one reason the CNBC TV host likes i",
      "url": "https://finnhub.io/api/news?id=ec5cbc07855d0332568210b79bf6655acd7aefc9b94b4a01a7e690edea34e13f"
    },
    {
      "headline": "Eli Lilly (LLY) Unveils Alzheimer's And CLL Trial Results With New LTZ Collaboration",
      "source": "Yahoo",
      "datetime": 1753897059,
      "summary": "Eli Lilly (LLY) has been actively progressing its pharmaceutical offerings and forging new alliances, as recent product results and collaborations indicate a commitment to innovation in Alzheimer's and blood cancer treatments. The continuous advancements with Kisunla and Jaypirca, alongside partners",
      "url": "https://finnhub.io/api/news?id=a709ce61ce3e7f305d93c3a0555f57171f9fa9005e9ffcd34b8ade39713452e5"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-07-25",
      "description": "xslF345X05/form4-07252025_040701.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925020284/xslF345X05/form4-07252025_040701.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753219662.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000196/xslF345X05/wk-form4_1753219662.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753217727.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000194/xslF345X05/wk-form4_1753217727.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753216439.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000188/xslF345X05/wk-form4_1753216439.xml"
    },
    {
      "form": "4",
      "date": "2025-07-22",
      "description": "xslF345X05/wk-form4_1753215735.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000184/xslF345X05/wk-form4_1753215735.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}